妊娠中期应用替比夫定控制乙型肝炎病毒携带孕妇病毒载量及其阻断母婴传播效果分析*

doi:10.3969/j.issn.1672-5069.2020.02.008

摘要/Abstract

摘要： 目的探讨在妊娠中期应用替比夫定控制乙型肝炎病毒携带孕妇病毒载量,观察其阻断HBV母婴传播的效果。方法 2016年2月～2018年2月我院就诊的60例妊娠中期HBV携带者被随机分为对照组30例和观察组30例。在妊娠6个月时,给予观察组替比夫定口服,直至分娩结束后1周,对照组孕妇不接受抗病毒治疗。两组新生儿出生后均常规注射重组乙肝疫苗和乙肝免疫球蛋白。采用酶联免疫吸附法检测血清白细胞介素-2(IL-2)、IL-4和IL-6水平。HBsAg)水平。采用实时荧光定量PCR法检测血清HBV DNA水平,采用电化学发光法检测血清HBsAg。结果治疗前,两组血清HBV DNA水平无统计学差异(P>0.05),分娩前,观察组血清HBV DNA水平为(3.7±0.7)lg copies/mL,显著低于对照组【(7.8±1.0)lg copies/mL,P<0.05】;分娩后,观察组血清IL-2水平为(20.6±2.7)pg/mL,显著高于对照组【(15.7±1.3)pg/mL,P<0.05】,血清IL-4水平为(19.7±1.5)pg/mL,显著低于对照组【(30.6±2.8)pg/mL,P<0.05】,血清IL-6水平为(21.5±4.2)pg/mL,显著低于对照组【(29.7±5.1)pg/mL,P<0.05】;两组新生儿胎龄、体质量、身长和Apgar评分比较无统计学差异(P>0.05);在新生儿6月龄和1岁时,观察组无HBV感染病例,而在对照组有1例(3.3%)患儿感染。结论在妊娠中期给予携带HBV孕妇替比夫定治疗可阻断HBV母婴传播,且对婴儿无不良影响。

关键词: 乙型肝炎病毒携带者, 替比夫定, 母婴传播, 新生儿, 妊娠

Abstract: Objective The aim of this study was to observe the efficacy of telbivudine on viral load loss and mother-to-child transmission in pregnant women with chronic hepatitis B viral carrier. Methods 60 pregnant women with HBV carrier were randomly divided into two groups in our hospital between February 2016 and February 2018, and 30 cases in the observation at six month of pregnancy were, while another 30 in the control were not given telbivudine until the end of delivery. All newborns were routinely injected with recombinant hepatitis B vaccine and hepatitis B immunoglobulin after birth. Serum HBV DNA, HBsAg, interleukin-2 (IL-2), IL-4 and IL-6 levels were assayed. Results Before anti-viral treatment, serum HBV DNA loads in the two groups were not significantly different (P>0.05), while serum HBV DNA level after delivery in the observation group was (3.7±0.7)lg copies/mL, significantly lower than 【(7.8±1.0)lg copies/mL, P<0.05】 in the control; after delivery, serum IL-2 level in the anti-viral group was (20.6±2.7)pg/mL, significantly higher than 【(15.7±1.3)pg/mL, P<0.05】, serum IL-4 level was (19.7±1.5)pg/mL, significantly lower than 【(30.6±2.8)pg/mL, P<0.05】, and serum IL-6 level was (21.5±4.2)pg/mL, much lower than 【(29.7±5.1)pg/mL, P<0.05】 in the control; the gestational age, height, body mass and Apgar’s scores of newborns in the two groups were not significantly different (P>0.05); at 6 month and one year follow-up, there was one infant having HBV infection in the control, while there was no infant infected in the observation. Conclusion We recommend oral telbivudine administration at second trimester of pregnancy for blocking mother-to-child HBV transmission in women carrying HBV, which might safe and efficacious.

Key words: Hepatitis B viral carrier, Telbivudine, Mother-to-child transmission, Newborns, Pregnancy

范凌, 杨军, 纪风兵, 周琴. 妊娠中期应用替比夫定控制乙型肝炎病毒携带孕妇病毒载量及其阻断母婴传播效果分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 179-182.

Fan Ling, Yang Jun, Ji Fengbing, et al. Efficacy of telbivudine on viral load loss and mother-to-child transmission in pregnant women with chronic hepatitis B viral carrier[J]. Journal of Practical Hepatology, 2020, 23(2): 179-182.

参考文献

[1] Li Y, Xia Y, Cheng X, et al. Hepatitis b surface antigen activates unfolded protein response in forming ground glass hepatocytes of chronic hepatitis B. Viruses, 2019, 11(4): 386.
[2] Huang C, Shen D, Sun S, et al. Effect of fufang biejia ruangan tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis b: protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies. Medicine (Baltimore), 2019, 98(17): 15297.
[3] Sun W, Zhao S, Ma L, et al. Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission. BMC Gastroenterol, 2017, 17(1): 51.
[4] Chang CY, Aziz N, Poongkunran M, et al. Serum aminotransferase flares in pregnant and postpartum women with current or prior treatment for chronic hepatitis B. J Clin Gastroenterol, 2018, 52(3): 255-261.
[5] Zeng J, Zheng C, Li H. Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy. Medicine (Baltimore), 2019, 98(14): 15092.
[6] Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology, 2016, 63(1): 284-306.
[7] Kang Y, Cai Y. Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy. J Hosp Infect, 2017, 96(4): 342-348.
[8] 赵媛, 曹维章, 房荣, 等. 慢性乙型肝炎患者血清suPAR和IP-1O水平及其临床意义. 实用肝脏病杂志, 2017, 20(3): 345-347.
[9] Chang CY, Aziz N, Poongkunran M, et al. Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B. Am J Gastroenterol, 2016, 111(10): 1410-1415.
[10] Anabire NG, Aryee PA, Abdul-Karim A, et al. Impact of malaria and hepatitis B co-infection on clinical and cytokine profiles among pregnant women. PLoS One, 2019, 14(4): 0215550.
[11] Zobel T, Bock CT, Kühl U, et al. Telbivudine reduces parvovirus b19-induced apoptosis in circulating angiogenic cells. Viruses, 2019, 11(3): 227.
[12] Zou S, Cheng Z, Song S, et al. Telbivudine-induced myopathy incidentally detected by fdg pet/ct imaging in a patient with history of hepatocellular carcinoma. Clin Nucl Med, 2019, 44(2): 171-172.
[13] Malik MU, Ucbilek E, Trilianos P, et al. Prophylaxis among hepatitis B core antibody-positive deceased-donor liver transplant recipients: hepatitis B immunoglobulin plus oral antiviral agents versus antiviral agents alone: a single-center experience. Exp Clin Transplant, 2017, 15(2): 183-188.
[14] Özgüler M, Akbulut A, DemirdağK, et al. Investigation by the method of inno-lipa of primary resistance to lamivudine in patients with chronic hepatitis B who have not used antiviral therapy. West Indian Med J, 2015, 65(1): 111-115.
[15] 廖金瑶, 肖艺, 黄晶, 等. 替比夫定与恩替卡韦对乙型肝炎病毒感染患者的治疗疗效研究. 中华医院感染学杂志, 2018, 28(7): 983-986.
[16] 林森, 张云桂, 周奇文, 等. HIV感染/AIDS患者相关支原体感染与免疫指标及炎症因子水平的关联性. 中华医院感染学杂志, 2019, 29(7): 976-979.
[17] Wang R, Fang S, Sun Q, et al. Congenital biliary atresia in an infant born to hepatitis b mother treated with telbivudine before and during pregnancy. Dig Liver Dis, 2018, 50(10): 1097-1098.
[18] Yan Z, Qiao B, Zhang H, et al. Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: a 104-week pilot study. Medicine (Baltimore), 2018, 97(31): 11716.
[19] Patel NH, Joshi SS, Lau KCK, et al. Analysis of serum hepatitis B virus RNA levels in a multiethnic cohort of pregnant chronic hepatitis B carriers. J Clin Virol, 2019, 111(1):42-47.
[20] Block TM, Gish R, Guo HT, et al.Chronic hepatitis B: What should be the goal for new therapies? Antiviral Res, 2013, 98(1): 27–34.
[21] Du J, Xu YY, Wang J, et al. 24 year outcomes of hepatitis B vaccination in Hangzhou, China. Hum Vaccin Immunother, 2015 ,11(8): 2051–2060.
[22] Ye YA, Li XK, Zhou DQ, et al. Chinese herbal medicine combined with entecavir for HBeAg positive chronic hepatitis B: study protocol for a multi-center, double-blind randomized-controlled trial. Chin J Integr Med, 2018, 24(9): 653-660.
[23] 张晨曦, 李少昊. 替比夫定与恩替卡韦治疗Peg-IFNα-2a不应答的血清HBeAg阳性的慢性乙型肝炎患者效果分析. 实用肝脏病杂志, 2018, 21(2): 281-282.
[24] Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol, 2015, 21(36): 10274–10289.
[25] Walker TY, Smith EA, Fenlon N, et al. Characteristics of pregnant women with hepatitis B virus infection in 5 US public health jurisdictions, 2008-2012. Public Health Rep, 2016 , 131(5): 685–694.

妊娠中期应用替比夫定控制乙型肝炎病毒携带孕妇病毒载量及其阻断母婴传播效果分析^*

Efficacy of telbivudine on viral load loss and mother-to-child transmission in pregnant women with chronic hepatitis B viral carrier

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	丁俊琪, 张偲, 张彬. 聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎部分应答患者序贯替比夫定治疗疗效观察^*[J]. 实用肝脏病杂志, 2020, 23(1): 26-29.
[2]	周晓旭, 张华杰, 商志娟. 速度向量成像技术定量参数评估妊娠期肝内胆汁淤积症孕妇胎儿心功能研究^*[J]. 实用肝脏病杂志, 2020, 23(1): 62-65.
[3]	陈慧婷, 周永健. 妊娠期肝内胆汁淤积症诊断与管理[J]. 实用肝脏病杂志, 2020, 23(1): 153-155.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[7]	汤人夷, 胡群凤, 彭莉晴. 妊娠期肝内胆汁淤积症患者血脂、肝功能和雌激素水平的变化及临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 860-863.
[8]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[9]	胡群凤, 杨莉. 112例妊娠期肝损害患者妊娠结局分析*[J]. 实用肝脏病杂志, 2019, 22(5): 664-667.
[10]	陈嵘, 黄美玲, 凌雪梅, 林小红, 曾俊, 黎云, 夏建红. 替比夫定联合HBIG和乙肝疫苗阻断HBV母婴传播临床效果分析*[J]. 实用肝脏病杂志, 2019, 22(5): 752-753.
[11]	严玲玲, 胡东辉, 黄艳芳. 腺苷蛋氨酸联合多烯磷酯酰胆碱治疗妊娠期肝内胆汁淤积症患者临床疗效初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 530-533.
[12]	张微, 史军梅, 王倩. 新生儿发生高胆红素血症危险因素分析[J]. 实用肝脏病杂志, 2019, 22(4): 534-536.
[13]	丁洋, 窦晓光. 如何实现乙型肝炎病毒母婴“零”传播?[J]. 实用肝脏病杂志, 2019, 22(1): 4-5.
[14]	林苏, 朱月永. 血清高病毒载量和乙型肝炎发作孕妇的抗病毒治疗^*[J]. 实用肝脏病杂志, 2019, 22(1): 13-16.
[15]	朱娅鸽, 雷春梅, 郭丹丹, 陈天艳. 慢性乙型肝炎病毒感染孕妇及其婴幼儿随访管理研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 45-48.